Invest in the U.S. Expansion of PLPC™ Platform
PLPC™ USA is the U.S. territorial commercialization vehicle of PLPC™ Platform, a structural phospholipoprotein biotechnology platform with potential applications across advanced nutraceuticals, ex vivo validation, NAM-oriented evidence, localized devices, wellness, longevity, biomedical data, STIP™-based traceability, AI-ready evidence infrastructure, and future dual-domain opportunities across civil, biomedical, defense-adjacent, critical-environment, and space-health applications.
Investment Window Parameters
| Global platform valuation | US$700M |
| U.S. territorial reference value | US$150M |
| Early Access Valuation | US$100M |
| Early Investor Discount | 33% |
| Maximum Allocation | Up to 10% |
A Global Platform. A U.S. Territorial Opportunity.
PLPC™ USA provides access to the U.S. territorial expansion of PLPC™ Platform through a specialized U.S. vehicle.
The United States represents one of the most relevant markets for biotechnology, advanced wellness, nutraceuticals, aesthetics, performance, longevity, localized devices, functional evidence, biomedical data, AI-ready evidence infrastructure, capital formation, strategic partnerships, and future dual-domain applications.
The Early Access Investment Window allows early investors to participate in PLPC™ USA at a preferred valuation of US$100M, compared with a U.S. territorial reference value of US$150M.
Global Validation
Backed by a globally recognized platform valued at US$700M.
Preferred Pricing
Access the territorial vehicle at a 33% discount relative to its reference value.
A Multi-Vertical Structural Biotechnology Platform
PLPC™ Platform is a structural phospholipoprotein biotechnology platform with potential to support multiple product, service, evidence, data, traceability, and commercialization lines.
PLPC™ Platform is not positioned as a single product. It is structured as a technology ecosystem with differentiated development lines and multiple potential pathways to value creation.
Advanced Nutraceuticals
Development focused on high-end formulations for wellness, functional metabolic support, and targeted ex vivo cellular differentiation.
- Bioactive lipids & phospholipoproteic complexes
- Targeted cellular wellness pathways
- Advanced encapsulation with structured delivery
Ex Vivo Validation
Proprietary methodology to map real-time metabolic and cellular response, establishing deep clinical/functional evidence lines.
- Custom cell line modeling and response mapping
- Quantitative metabolic profiling
- Rapid validation cycles bypassing animal testing
NAM-oriented Evidence
Adhering to the modern FDA Modernization Act guidelines by utilizing human-relevant New Approach Methodologies (NAM) for evidence building.
- In vitro and in silico toxicity testing
- Patient-specific cellular assay systems
- Accelerated regulatory alignment profile
Localized Devices
Hardware and diagnostic tools development subject to specific intended uses, claims, and regulatory class certifications.
- Targeted delivery and monitoring equipment
- Integration with the STIP™ profiling database
- Modular configurations for clinical setups
Advanced Wellness
Targeting the premium functional wellness market with an focus on metabolic support, long-term longevity metrics, and performance.
- Premium longevity formulation lines
- Metabolic optimization regimes
- Personalized dynamic wellness programs
Aesthetics / Performance
Developing premium commercial applications targeting physical performance, skin structure, and cell vitality optimization.
- Structural cellular formulas for skin and muscle
- Targeted commercial aesthetic partnerships
- Dermatological active complex validation
STIP™ Platform
Structural Traceability and Integrated Profiling Platform: The digital and data backbone linking scientific claims to real batch evidence.
- Secure distributed ledger for product batches
- Dynamic evidence mapping and claims validation
- Real-time technical data room access
What Is PLPC™ USA?
PLPC™ USA has been conceived to execute the commercial, strategic, regulatory, documentation, data, partnership, and investment expansion of PLPC™ Platform in the United States.
PLPC™ USA allows investors to focus on the U.S. opportunity without transferring the full global platform.
Structural Breakdown
| Vehicle | PLPC™ USA |
| Territory | United States |
| Function | Commercialization, partnerships, regulatory strategy, capital formation |
| Base Platform | PLPC™ Platform |
| Global IP | Remains controlled by the parent company |
| Critical Manufacturing | Centralized by parent company or authorized partner |
| Traceability | STIP™ Infrastructure |
A Priority Market for Expansion, Capital, Data, and Adoption
The United States concentrates key conditions for a platform such as PLPC™, creating a highly valuable territorial opportunity.
Deep Capital Markets
Access to deep private capital markets and the largest pool of biotech investors in the world.
Structured Formation
Authorized investment portals and structured capital formation pathways for securities compliance.
Premium Markets
Unmatched adoption and spend capacity in wellness, aesthetics, nutraceuticals, performance, and longevity.
Innovation Ecosystems
Thriving biotechnology and health innovation hubs enabling rapid trial and scaling.
Strategic Partners
Direct accessibility to clinics, distributors, KOLs, advisors, and corporate alliances.
Pricing Capacity
Premium pricing capacity driven by a strong market demand for high-end biomedical evidence.
Regulatory Relevance
High compliance value in an FDA-facing jurisdiction and standardized clinical evidence guidelines.
Commercial Channels
Robust B2B, B2C, out-licensing, and joint co-development potential with global players.
Biomedical Data & AI
Deep biomedical data accumulation and AI-ready evidence infrastructure opportunities.
Dual-Domain Relevance
Future potential in resilience, remote health, defense-adjacent, critical-environment, and space-health.
Strategic Launchpad
Dedicated corporate structure to serve as a platform for subsequent capital rounds and international expansion.
Why PLPC™ USA Is a Distinct Opportunity
Compare the structural and strategic differentiators that set PLPC™ USA apart from binary-risk biotech companies.
| Strategic Differentiator | Operational Value for Investors |
|---|---|
| Multi-vertical Platform | Diversified downside risk: business model does not depend on a single product or commercial line success, spanning nutraceuticals, validation, devices, data, and dual-domain applications. |
| Ex Vivo Evidence Base | Cellular and metabolic functional data room providing robust initial differentiation. |
| NAM-oriented Evidence | Aligns with global FDA Modernization Act trends, avoiding lengthy animal validation processes. |
| STIP™ Traceability | Full database tracing, evidence mapping, and absolute governance over marketing claims. |
| Protected Global IP | Parent company retains global IP and know-how, shielding the U.S. commercial vehicle from core technology liabilities. |
| U.S. Territorial Vehicle | Clean target corporate structure solely focused on U.S. commercial exploitation, capital formation, and strategic partnerships. |
| Preferred Entry Valuation | Early Access Investment Window at US$100M, representing a 33% discount from the US$150M territorial reference value. |
Science. Documentation. Traceability.
PLPC™ Platform has a scientific and documentary support base that includes indexed publications, ex vivo evidence, institutional resources, technical materials, international congresses, structured documentation, and traceability through STIP™.
Functional Profiling Validation
Figure displays ex vivo molecular response profiles showing localized cellular metabolic integrity validation vs standard control vectors.
Public Resources
These resources allow interested investors, advisors, and strategic partners to review public information related to the platform, publications, associated programs, academic profiles, and available scientific documentation.
PLPC™ Platform Registry
Official global technology site and dataset
OGRD Alliance
International scientific organization coordinator
ONCOVIX Program
Associated international clinical-operational framework
Founder Academic Profile (ORCID)
Dr. Gutiérrez's official biomedical researcher registration
PubMed OGRD Alliance
Search indexed papers in the National Library of Medicine
Early Access at a Preferred Valuation
PLPC™ USA contemplates an Early Access Investment Window at a US$100M valuation.
Key Financial Allocations
| U.S. Territorial Reference Value | US$150M |
| Early Access Valuation | US$100M |
| Early Investor Discount | 33% |
| Maximum Allocation | Up to 10% |
| Maximum Capacity | Up to US$10M |
| Estimated First Tranche | Up to US$5M (subject to legal structure) |
Interactive Calculator
Select a hypothetical total capitalization target to calculate the corresponding approximate territorial vehicle equity allocation:
*Calculations based on a fixed Early Access valuation of US$100M. Final allocation will depend on the amount raised, applicable legal structure, selected authorized investment portal, final offering documents, legal review, investor eligibility, and applicable regulations.
Intended Use of Funds
Funds are expected to support both platform rights activation and U.S. execution.
U.S. Expansion Focus
The objective is to convert capital into territorial traction, platform rights activation, partnerships, regulatory readiness, commercial presence, documentation discipline, biomedical data organization, STIP™ traceability, AI-ready evidence infrastructure, and investor readiness for future rounds.
- Activate U.S. territorial rights
- Deploy STIP™ traceability nodes
- Prepare organized biomedical database
Who This Opportunity Is For
PLPC™ USA corresponds to a high-value community of strategic and early-stage investors interested in advanced biotechnology, longevity platforms, and U.S. territorial expansion.
Target Investor Interests
PLPC™ USA may be relevant for investors interested in:
*Final participation levels will be subject to the final investment structure, selected authorized investment portal, final offering documents, investor eligibility, and applicable regulations.
Suggested Allocations & Benefits
Click on any tier below to automatically select it in the registration form:
Join the Priority Access List
The investment process is currently in preparation. Interested individuals may request priority access to receive updates, launch information, and access to the official investment pathway when available.
By registering, interested participants may receive:
Window Opening Alert
Notice of opening of the investment window.
Investor Disclosures
Access to public investor materials and briefings.
Informational Webinars
Invitation to informational webinars with the founder.
Valuation & Fund Updates
Updates on valuation and use of funds.
Official Investment Pathway
Information on the official investment pathway.
Definitive Terms
Final terms when available.
FAQs & Resources
Access to FAQs and supporting resources.
U.S. Expansion Progress
Selected updates on platform rights activation, STIP™ traceability, biomedical data infrastructure, and U.S. expansion progress.
Access Request Confirmed
Thank you, Investor
We have registered your interest in the US$1,000–5,000 allocation. A confirmation email has been dispatched with early disclosures.
Request Priority Access
Frequently Asked Questions
Get answers to key structural, financial, and regulatory questions regarding the PLPC™ USA offering.
Join the PLPC™ USA Priority Access List
Access early information about the U.S. territorial investment opportunity of PLPC™ Platform.